{
  "document_category": "legal-advice",
  "document_name": "114901f.pdf",
  "chunk_index": 8,
  "chunk_text": "See 21 USC § 355 (j)(2)(A)(vii)(2010) (quoted in\nAddendum A). 26 The term “paragraph IV certification” is further explained in Addendum A. 27 The term “bioequivalence” is defined in Addendum A. POSTU-139175-10 34 paragraph 2, except that a court may award attorney fees under [35 U.S.C.] section\n285.”). 28 Thus, other than an award of fees and costs pursuant to 35 U.S.C. § 285 for an\nexceptional case (e.g., frivolous paragraph IV certification or trial misconduct),29 the\npotential statutory remedies available to the plaintiffs, given their infringement actions\nwere based on 35 U.S.C. § 271(e)(2), were those set forth in 35 U.S.C. § 271(e)(4),\nparaphrased as follows:\n(A) An order that the effective date of the FDA approval of the ANDA be no\nearlier than expiration of the patent (i.e., delaying the marketing and\nselling of the ANDA products); (B) An injunction to prevent commercialization of the ANDA products until the\npatents expire; (C) Only if the ANDA products were commercialized, damages or other\nmonetary relief; and (D) For infringement by a biological product, a permanent injunction in certain\ncircumstances.30 The flush language of 35 U.S.C. § 271(e)(4) provides (emphasis added): The remedies prescribed by subparagraphs (A), (B), (C), and (D)\nare the only remedies which may be granted by a court for an act of\ninfringement described in paragraph (2), except that a court may\naward attorney fees under section 285. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------28 The current statute includes subparagraph (d) relative to biologics, as discussed below. 29 35 U.S.C. § 285 provides that “The court in exceptional cases may award reasonable attorney fees to\nthe prevailing party. See Glaxo Group Limited v. Apotex, Inc., 376 F.3d 1339 (Fed. Cir. 2004)\n(addressing exceptional cases). See also Takeda Chem. Indus., Ltd. v. Mylan Labs., Inc., 459 F.Supp.2d\n227, 245-252 (S.D.N.Y. 2006) (“Sanctions Opinion”) and 2007 WL 840368 (S.D.N.Y. Mar. 21, 2007)\n(“Amount Opinion”), aff’d and rehearing en banc denied, 549 F.3d 1381 (Fed. Cir. 2009), cert. denied 130\nS. Ct. 106 (2009) (attorneys fees awarded for bad faith filing of the Paragraph IV certification and\nmisconduct during litigation). 30 See Addendum A, footnote 66 (status of amendments enacted as part of the 2010 health care reform). POSTU-139175-10 35 ----------------------------------------------------------------------------------------------------------------------------------none of the complaints alleged loss of profits.31\nCorporation X, in each law suit, in addition to denying its ANDA products would infringe\nthe patent claims that the plaintiffs alleged would be infringed:\n• denied that the patent claims that the plaintiffs alleged would be infringed were\nvalid; • asserted affirmative defenses that the patent claims that the plaintiffs alleged\nwould be infringed were invalid; and • counterclaimed that the patent claims the plaintiffs alleged would be infringed\nwere invalid. Corporation X’s prayers for relief requested that the patent claims at issue, which\nplaintiffs alleged were infringed by Corporation X filing the ANDAs, be declared invalid. -----------------------------------------------------------Thus, the pleadings were joined on the issues of infringement and validity. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------32 none of the claims included in the lawsuits filed against Corporation X,\nand none of Corporation X’s counterclaims, arose from a cause of action other than the\n31"
}